Abiraterone Acetate in Molecular Apocrine Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 15, 2015

Study Completion Date

July 4, 2018

Conditions
Breast Cancer
Interventions
DRUG

Abiraterone Acetate

Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.

Trial Locations (36)

Unknown

Ico - Site Paul Papin, Angers

Institut Sainte Catherine, Avignon

Chu - Hopital Jean Minjoz, Besançon

Institut Bergonie, Bordeaux

Polyclinique Bordeaux Nord Aquitaine, Bordeaux

Chu de Brest - Hôpital Morvan, Brest

Centre Francois Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Ch Alpes Leman, Contamine-sur-Arve

Centre Georges-François Leclerc, Dijon

Chu de Grenoble - Hopital Michallon, Grenoble

Clinique Sainte Marguerite, Hyères

Chd de Vendee, La Roche-sur-Yon

Centre Oscar Lambret, Lille

Centre Leon Berard, Lyon

Institut Paoli Calmettes, Marseille

Ch de Mont de Marsan, Mont-de-Marsan

Centre Antoine Lacassagne, Nice

Chr D Orleans - Hopital La Source, Orléans

Hôpital Saint-Louis, Paris

Hôpital Tenon, Paris

Institut Curie - Hôpital Claudius Regaud, Paris

Ch de Perpignan, Perpignan

Ch Lyon Sud, Pierre-Bénite

CH de la Région d'Annecy, Pringy

Institut Jean Godinot, Reims

Centre Henri Becquerel, Rouen

Institut Curie - Hôpital René Huguenin, Saint-Cloud

Ico- Site Rene Gauducheau, Saint-Herblain

Centre Paul Strauss, Strasbourg

Hopital Civil - Strasbourg, Strasbourg

Hopitaux Du Leman, Thonon-les-Bains

Institut Claudius Regaud, Toulouse

Ch Bretagne Atlantique, Vannes

Hôpital Privé Océane, Vannes

Gustave Roussy Cancer Campus, Villejuif

All Listed Sponsors
lead

UNICANCER

OTHER

NCT01842321 - Abiraterone Acetate in Molecular Apocrine Breast Cancer | Biotech Hunter | Biotech Hunter